The expressions of PD-L2, TIM3, and CCR4 were lower than those of the RM1 group, so it can be considered that the regulator of m6A is closely related to the malignant degree, prognosis, and anti-tumor immune response of breast cancer and can be used as a potential target and biological target for breast cancer immunotherapy. The gene discussed is PDCD1LG2; the disease is breast carcinoma.